Work

Treatment with the Smallpox Antiviral Tecovirimat (ST-246) Alone or in Combination with ACAM2000 Vaccination Is Effective as a Postsymptomatic Therapy for Monkeypox Virus Infection

Year: 2015

Type: article

Abstract: The therapeutic efficacies of smallpox vaccine ACAM2000 and antiviral tecovirimat given alone or in combination starting on day 3 postinfection were compared in a cynomolgus macaque model of lethal monkeypox virus infection. Postexposure administration of ACAM2000 alone did not provide any protection against severe monkeypox disease or mortality. In contrast, postexposure treatment with tecovirimat alone or in combination with ACAM2000 provided full protection. Additionally, tecovirimat treatment delayed until day 4, 5, or 6 postinfection was 83% (days 4 and 5) or 50% (day 6) effective.

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.00208-15

Authors: Aklile Berhanu, Jonathan T. Prigge, Peter M. Silvera, Kady M. Honeychurch, Dennis E. Hruby, Douglas W. Grosenbach

Institutions: Siga Technologies (United States), Southern Research Institute

Language: English

Topic: Poxvirus research and outbreaks

Subfield: Virology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Public Health Service, National Institute of Nursing Research, National Institute of Allergy and Infectious Diseases